KR20200128032A - Ampa 수용체 기능을 조절하는 화합물 - Google Patents

Ampa 수용체 기능을 조절하는 화합물 Download PDF

Info

Publication number
KR20200128032A
KR20200128032A KR1020207025799A KR20207025799A KR20200128032A KR 20200128032 A KR20200128032 A KR 20200128032A KR 1020207025799 A KR1020207025799 A KR 1020207025799A KR 20207025799 A KR20207025799 A KR 20207025799A KR 20200128032 A KR20200128032 A KR 20200128032A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
compounds
mmol
formula
Prior art date
Application number
KR1020207025799A
Other languages
English (en)
Korean (ko)
Inventor
사이먼 와드
폴 베스윅
루이스 페니콧
트리스탄 레윌런
이리나 척코우리
캐롤리나 빌라롱가-바버
로데릭 알란 포터
Original Assignee
유니버시티 칼리지 카디프 컨설턴츠 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 칼리지 카디프 컨설턴츠 리미티드 filed Critical 유니버시티 칼리지 카디프 컨설턴츠 리미티드
Publication of KR20200128032A publication Critical patent/KR20200128032A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207025799A 2018-03-01 2019-03-01 Ampa 수용체 기능을 조절하는 화합물 KR20200128032A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1803340.7 2018-03-01
GBGB1803340.7A GB201803340D0 (en) 2018-03-01 2018-03-01 Compounds
PCT/GB2019/050578 WO2019166822A1 (en) 2018-03-01 2019-03-01 Compounds that modulates ampa receptor function

Publications (1)

Publication Number Publication Date
KR20200128032A true KR20200128032A (ko) 2020-11-11

Family

ID=61903711

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025799A KR20200128032A (ko) 2018-03-01 2019-03-01 Ampa 수용체 기능을 조절하는 화합물

Country Status (16)

Country Link
US (2) US11298345B2 (pl)
EP (1) EP3759092B1 (pl)
JP (1) JP7225255B2 (pl)
KR (1) KR20200128032A (pl)
CN (1) CN112004811B (pl)
AU (1) AU2019226718C1 (pl)
BR (1) BR112020017739A2 (pl)
CA (1) CA3091783A1 (pl)
DK (1) DK3759092T3 (pl)
ES (1) ES2970784T3 (pl)
FI (1) FI3759092T3 (pl)
GB (1) GB201803340D0 (pl)
MX (1) MX2020009097A (pl)
PL (1) PL3759092T3 (pl)
RU (1) RU2020127537A (pl)
WO (1) WO2019166822A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
DE60137426D1 (de) * 2000-06-12 2009-03-05 Eisai R&D Man Co Ltd 1,2-dihydropyridinverbindungen, verfahren zu deren herstellung und deren verwendung
WO2004046137A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
DE602006018122D1 (de) 2005-04-12 2010-12-23 Vicore Pharma Ab Neue tricyclische angiotensin-ii-agonisten
EP1996555A1 (en) 2006-03-20 2008-12-03 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
AU2007244971B2 (en) 2006-04-24 2012-01-19 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ATE502675T1 (de) 2006-11-03 2011-04-15 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
GB0711088D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
KR20100063087A (ko) 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
GB0721094D0 (en) 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
CA2723039A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
SG176828A1 (en) 2009-06-26 2012-01-30 Pfizer Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
WO2011132051A2 (en) * 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Also Published As

Publication number Publication date
CN112004811B (zh) 2023-09-22
DK3759092T3 (da) 2024-01-22
US11298345B2 (en) 2022-04-12
EP3759092B1 (en) 2023-12-20
BR112020017739A2 (pt) 2020-12-22
AU2019226718C1 (en) 2024-01-11
CA3091783A1 (en) 2019-09-06
PL3759092T3 (pl) 2024-04-08
JP2021515749A (ja) 2021-06-24
EP3759092A1 (en) 2021-01-06
AU2019226718A1 (en) 2020-09-03
GB201803340D0 (en) 2018-04-18
US20230000847A1 (en) 2023-01-05
AU2019226718A8 (en) 2020-09-24
AU2019226718B2 (en) 2023-09-28
WO2019166822A1 (en) 2019-09-06
FI3759092T3 (fi) 2024-01-18
MX2020009097A (es) 2020-10-08
RU2020127537A (ru) 2022-04-26
ES2970784T3 (es) 2024-05-30
CN112004811A (zh) 2020-11-27
US20210113539A1 (en) 2021-04-22
JP7225255B2 (ja) 2023-02-20

Similar Documents

Publication Publication Date Title
JP5397950B2 (ja) １，４−ジ置換３−シアノピリドン誘導体とそれらのポジティブｍＧｌｕＲ２−受容体モジュレーター
US20230000847A1 (en) Compounds that modulates ampa receptor function
EA016969B1 (ru) 1,3-двузамещенные-4-фенил-1н-пиридин-2-оны
US20140088151A1 (en) Alhydroxymethyl biaryl benzotriazole derivatives
RU2387644C2 (ru) Циклопропилпиперидиновые ингибиторы транспортера глицина
AU2012219537B2 (en) (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR
JP6703131B2 (ja) 新規なｎ−［（ピリミジニルアミノ）プロパニル］−およびｎ−［（ピリジニルアミノ）プロパニル］アリールカルボキサミド
JP2016511262A (ja) 置換二環式ジヒドロピリミジノン及び好中球エラスターゼ活性の阻害薬としてのそれらの使用
KR20130122531A (ko) Ｍｇｌｕｒ５ 양성 알로스테릭 조절물로서 치환된 ６­메틸니코틴아미드
JP7014808B2 (ja) Ａｍｐａ受容体増強薬
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡
KR20120097400A (ko) Ｍｇｌｕｒ５ 리셉터의 알로스테릭 조절자로서의 비사이클릭 티아졸
EP4301751A1 (en) Pyrimidine or pyridine derivates useful as hcn2 modulators